Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22752| Title: | Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts. | Austin Authors: | Yang, J C-H;Ramalingam, S S;Lee, C K;Kurata, T;Kim, D-W;John, Thomas ;Nogami, N;Ohe, Y;Rukazenkov, Y;Murphy, M;Jänne, P A | Affiliation: | National Taiwan University and National Taiwan University Cancer Center, Taipei City, Taiwan Austin Health, Heidelberg, Victoria, Australia St. George Hospital, Sydney, Australia Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Emory School of Medicine, Winship Cancer Institute, Atlanta, GA, USA Kansai Medical University Hospital, Osaka, Japan Seoul National University Hospital, Seoul, Republic of Korea National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan AstraZeneca, Cambridge, UK Dana-Farber Cancer Institute, Boston, MA, USA |
Issue Date: | Apr-2019 | Publication information: | Annals of oncology : official journal of the European Society for Medical Oncology 2019; 30 Suppl 2: ii48 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/22752 | DOI: | 10.1093/annonc/mdz063.020 | Journal: | Annals of oncology : official journal of the European Society for Medical Oncology | PubMed URL: | 32131238 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.